The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Open accessAbstract
TGR5 is a G protein-coupled receptor expressed in brown adipose tissue and muscle, where its activation by bile acids triggers an increase in energy expenditure and attenuates diet-induced obesity. Using a combination of pharmacological and genetic gain- and loss-of-function studies in vivo, we show here that TGR5 signaling induces intestinal glucagon-like peptide-1 (GLP-1) release, leading to improved liver and pancreatic function and enhanced glucose tolerance in obese mice. In addition, we show that the induction of GLP-1 release in enteroendocrine cells by 6alpha-ethyl-23(S)-methyl-cholic acid (EMCA, INT-777), a specific TGR5 agonist, is linked to an increase of the intracellular ATP/ADP ratio and a subsequent rise in intracellular calcium mobilization. Altogether, these data show that the TGR5 signaling pathway is critical in regulating intestinal GLP-1 secretion in vivo, and suggest that pharmacological targeting of TGR5 may constitute a promising incretin-based strategy for the treatment of diabesity and associated metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bacteria-derived secondary bile acids (lithocholic acid, deoxycholic acid) can activate the G-protein coupled bile acid receptor Gpbar1 receptor (TGR5) in L cells, promoting the peripheral release of GLP-1 and PYY (Katsuma et al., 2005;Thomas et al., 2009;Ullmer et al., 2013).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2009
Experimental — accuracy not yet measuredIn the citing paper
“Bile acids induce insulin secretion directly via the transmembrane bile acid receptor Takeda G protein–coupled receptor 5 (on β cells and indirectly via stimulation of l-cell derived GLP-1 and subsequent insulin release (110–112).”
From Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease (2018) · cites this paper as [112]
In the citing paper
“TGR5 is therefore a new and attractive target for treating obesity, since it can theoretically protect against obesity and its complications via two distinct and potentially synergistic mechanisms: increased energy expenditure and improved insulin sensitivity 148.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]
In the citing paper
“Bile acids also increase energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin. This effect is dependent on induction of the type 2 iodothyronine deiodinase and is mediated by the binding of bile acids to a novel G-protein-coupled receptor TGR5 148.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]
In the citing paper
“Bile acids also increase energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin. This effect is dependent on induction of the type 2 iodothyronine deiodinase and is mediated by the binding of bile acids to a novel G-protein-coupled receptor TGR5 148.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]
In the citing paper
“One promising TGR5 agonist, INT-777, has already shown efficacy in vivo, increasing energy expenditure and reducing adiposity in mice with diet-induced obesity 148,149.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
A G Protein-coupled Receptor Responsive to Bile Acids
Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., & Tsujimoto, G. (2004) · Nature Medicine · doi:10.1038/nm1168 · Cited by 1,580
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21025 · Cited by 1,425
Self-citationTargeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422 · cited 2×
“The complete absence of changes in the expression level of classical target genes of FXR in the liver, such as cholesterol 7a hydroxylase (CYP7A1) and bile salt export pump (BSEP) (Thomas et al., 2008), further confirmed the specificity of INT-777 toward TGR5 (Figure S6B).”
BackgroundSelf-citationIdentification of membrane-type receptor for bile acids (M-BAR)
Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., & Tanaka, K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02550-0 · Cited by 993
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 974
Cited by
Sorted by citations
Items 701–800 of 999
Yao, T., Gu, X., Liang, X., Fall, F. N., Cao, A., Zhang, S., Guan, Y., Sun, B., & Xue, M. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737012 · Cited by 48
Intestinal microbiota and their metabolic contribution to type 2 diabetes and obesity
Cunningham, A., Stephens, J. W., & Harris, D. A. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00858-4 · Cited by 49
Microbial sensing in the intestine
Wan, T., Wang, Y., He, K., & Zhu, S. (2023) · Protein & Cell · doi:10.1093/procel/pwad028 · Cited by 50
Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols
Tveter, K. M., Mezhibovsky, E., Wu, Y., & Roopchand, D. E. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108457 · Cited by 52
Physiological activation of human and mouse bitter taste receptors by bile acids
Ziegler, F., Steuer, A., Pizio, A. D., & Behrens, M. (2023) · Communications Biology · doi:10.1038/s42003-023-04971-3 · Cited by 54
Zangerolamo, L., Carvalho, M. U. W. B. D., & Barbosa, H. C. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146547 · Cited by 56
Sangle, G. V., Lauffer, L. M., Grieco, A. J., Trivedi, S., Iakoubov, R., & Brubaker, P. L. (2011) · Endocrinology · doi:10.1210/en.2011-1732 · Cited by 47
Akinrotimi, O., Riessen, R., VanDuyne, P., Park, J. E., Lee, Y., Wong, L., Zavacki, A. M., Schoonjans, K., & Anakk, S. (2017) · Hepatology · doi:10.1002/hep.29305 · Cited by 50
Self-citationTGR5 Receptor Activation Attenuates Diabetic Retinopathy Through Suppression of RhoA/ROCK Signaling
Zhu, L., Wang, W., Xie, T., Zou, J., Nie, X., Wang, X., Zhang, M., Wang, Z., Gu, S., Zhuang, M., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201902496rr · Cited by 47
Hui, S., Huang, L., Wang, X., Zhu, X., Zhou, M., Chen, M., Yi, L., & Mi, M. (2020) · The FASEB Journal · doi:10.1096/fj.201902618rr · Cited by 48
Eslami, M., Bahar, A., Hemati, M., Nejad, Z. R., Mehranfar, F., Karami, S., Kobyliak, N. M., & Yousefi, B. (2020) · Diabetic Medicine · doi:10.1111/dme.14415 · Cited by 49
MASLD development: From molecular pathogenesis toward therapeutic strategies
Yang, Z., Zhao, J., Xie, K., Tang, C., Gan, C., & Gao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003629 · Cited by 49
Bile acids: emerging role in management of liver diseases
Asgharpour, A., Kumar, D. P., & Sanyal, A. J. (2015) · Hepatology International · doi:10.1007/s12072-015-9656-7 · Cited by 47
Macrophage Activation by Ursolic and Oleanolic Acids during Mycobacterial Infection
López-García, S., Castañeda‐Sánchez, J. I., Jiménez-Arellanes, M. A., Domínguez‐López, M. L., Castro-Mussot, M. E., Hernández‐Sánchez, J., & Luna‐Herrera, J. (2015) · Molecules · doi:10.3390/molecules200814348 · Cited by 46
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 45
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development
Jiang, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16464 · Cited by 49
Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects
Murakami, M., 宇根直子, Nishizawa, M., Suzuki, S., Ito, H., & Horiuchi, T. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-20 · Cited by 46
Brønden, A., Albèr, A., Rohde, U., Gasbjerg, L. S., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13080 · Cited by 45
Yang, F., Wang, Y., Li, G., Xue, J., Chen, Z., Jin, F., Luo, L., Zhou, X., Ma, Q., Cai, X., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14126 · Cited by 47
Shima, K. R., Ota, T., Kato, K., Takeshita, Y., Misu, H., Kaneko, S., & Takamura, T. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000469 · Cited by 47
Metabolic Effects of Bile Acids: Potential Role in Bariatric Surgery
Flynn, C. R., Albaugh, V. L., & Abumrad, N. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.014 · Cited by 48
The human microbiota is associated with cardiometabolic risk across the epidemiologic transition
Fei, N., Bernabé, B. P., Lie, L., Baghdan, D., Bedu-Addo, K., Plange‐Rhule, J., Forrester, T., Lambert, E. V., Bovet, P., Gottel, N., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215262 · Cited by 52
Bruce‐Keller, A. J., Richard, A. J., Fernandez-Kim, S.-O., Ribnicky, D., Salbaum, J. M., Newman, S. S., Carmouche, R. P., & Stephens, J. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-58005-7 · Cited by 47
Muscle-specific TGR5 overexpression improves glucose clearance in glucose-intolerant mice
Sasaki, T., Watanabe, Y., Kuboyama, A., Oikawa, A., Shimizu, M., Yamauchi, Y., & Sato, R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.016203 · Cited by 47
The Potential of Bile Acids as Biomarkers for Metabolic Disorders
Yin, C., Zhong, R., Zhang, W., Liu, L., Chen, L., & Zhang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512123 · Cited by 45
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph–ephrin system
Castelli, R., Tognolini, M., Vacondio, F., Incerti, M., Pala, D., Callegari, D., Bertoni, S., Giorgio, C., Hassan‐Mohamed, I., Zanotti, I., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.048 · Cited by 48
Cho, Y. M., Wideman, R. D., & Kieffer, T. J. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.4.262 · Cited by 47
Chen, W.-D., Yu, D. D., FORMAN, B. M., Huang, W., & Wang, Y.-D. (2012) · Hepatology · doi:10.1002/hep.26019 · Cited by 45
RetractedWang, S., Yang, Z., Xiong, F., Chen, C., Chao, X., Huang, J., & Huang, H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.06.019 · Cited by 45
Ahmad, M. I., Ijaz, M. U., Hussain, M., Haq, I. U., Zhao, D., & Li, C. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c02570 · Cited by 44
Svensson, P., Olsson, M. M., Andersson‐Assarsson, J. C., Taube, M., Pereira, M. J., Froguel, P., & Jacobson, P. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.031 · Cited by 49
Incretins or Anti-Incretins? A New Model for the “Entero-Pancreatic Axis”
Kamvissi, V., Salerno, A., Bornstein, S. R., Mingrone, G., & Rubino, F. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1394374 · Cited by 44
Keitel, V., & Häussinger, D. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835f3f14 · Cited by 44
Novel bile acid therapeutics for the treatment of chronic liver diseases
Hegade, V. S., Speight, A., Etherington, R. E., & Jones, D. E. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16630712 · Cited by 44
Recent advances in metabolic and bariatric surgery
Albaugh, V. L., Flynn, C. R., Tamboli, R. A., & Abumrad, N. N. (2016) · F1000Research · doi:10.12688/f1000research.7240.1 · Cited by 44
Marino, S. D., Carino, A., Masullo, D., Finamore, C., Marchianò, S., Cipriani, S., Leva, F. S. D., Catalanotti, B., Novellino, E., Limongelli, V., et al. (2017) · Scientific Reports · doi:10.1038/srep43290 · Cited by 45
Ito, K., Okumura, A., Takeuchi, J. S., Watashi, K., Inoue, R., Yamauchi, T., Sakamoto, K., Yamashita, Y., Iguchi, Y., Une, M., et al. (2021) · Hepatology · doi:10.1002/hep.31712 · Cited by 44
Liang, C., Zhou, X.-H., Gong, P.-M., Niu, H.-Y., Lyu, L., Wu, Y., Han, X., & Zhang, L. (2021) · Food & Function · doi:10.1039/d1fo00260k · Cited by 44
Advances in understanding the role of gut microbiota in fat deposition and lipid metabolism
Zhong, Y., Lei, Y., Jiang, S. H., Chen, D., Wang, X., Wang, K., Liao, T., Liao, R., Gan, M., Niu, L., et al. (2025) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-025-01284-9 · Cited by 45
Role of Nuclear Receptors in Lipid Dysfunction and Obesity-Related Diseases
Swanson, H. I., Wada, T., Xie, W., Renga, B., Zampella, A., Distrutti, E., Fiorucci, S., Kong, B., Thomas, A., Guo, G. L., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048694 · Cited by 45
Roles of Ileal ASBT and OSTα-OSTβ in Regulating Bile Acid Signaling
Dawson, P. A. (2017) · Digestive Diseases · doi:10.1159/000450987 · Cited by 44
Fluitman, K. S., de Clercq, N. C., Keijser, B. J. F., Visser, M., Nieuwdorp, M., & IJzerman, R. G. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1318060 · Cited by 47
CREB/CRTC2 controls GLP‐1‐dependent regulation of glucose homeostasis
Lee, J., Wen, X., Cho, H., & Koo, S. (2017) · The FASEB Journal · doi:10.1096/fj.201700845r · Cited by 43
Zhai, H., Li, Z., Peng, M., Huang, Z., Qin, T., Chen, L., Li, H., Zhang, H., Zhang, W., & Xu, G. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.026 · Cited by 45
Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis
van de Peppel, I. P., Bodewes, F. A. J. A., Verkade, H. J., & Jonker, J. W. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.08.009 · Cited by 43
The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism
Lefort, C., & Cani, P. D. (2021) · Cells · doi:10.3390/cells10020400 · Cited by 44
Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
Wang, D., Liu, J. Y., Zhou, L., Zhang, Q., Li, M., & Xiao, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.905171 · Cited by 48
Probing the Binding Site of Bile Acids in TGR5
Macchiarulo, A., Gioiello, A., Thomas, C., Pols, T. W. H., Nuti, R., Ferrari, C., Giacchè, N., Franco, F., Pruzanski, M., Auwerx, J. H., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400247k · Cited by 43
Self-citationBrønden, A., Albèr, A., Rohde, U., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01091 · Cited by 43
Di, S., Wang, Y., Han, L., Bao, Q. D., Gao, Z., Wang, Q., Yang, Y., Zhao, L., & Tong, X. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2958920 · Cited by 43
Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles
Zhang, B., Kuipers, F., de Boer, J. F., & Kuivenhoven, J. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010004 · Cited by 43
Zhang, L., Liu, Y., Xinzhou, W., & Zhang, X. (2023) · Nutrients · doi:10.3390/nu15061539 · Cited by 49
Bile Acids Have the Gall to Function as Hormones
Vallim, T. Q. D. A., & Edwards, P. A. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.005 · Cited by 44
Lee, W., Um, J., Hwang, B., Lee, Y. C., Chung, B. C., & Hong, J. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105539 · Cited by 41
The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?
Qi, Y., Duan, G., Wei, D., Zhao, C., & Ma, Y. (2022) · Molecules · doi:10.3390/molecules27165292 · Cited by 41
Wei, X., Yin, F., Wu, M., Xie, Q., Zhao, X., Zhu, C., Xie, R.-Q., Chen, C., Liu, M., Wang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.011 · Cited by 41
Current progress in the hypoglycemic mechanisms of natural polysaccharides
Tang, C., Zhou, R., Cao, K., Liu, J., Kan, J., Qian, C., & Jin, C. (2023) · Food & Function · doi:10.1039/d3fo00991b · Cited by 45
Update on the development of TGR5 agonists for human diseases
Jin, W., Zheng, M., Chen, Y., & Xiong, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116462 · Cited by 46
Młynarska, E., Wasiak, J., Gajewska, A., Steć, G., Jasińska, J., Rysz, J., & Franczyk, B. (2024) · Nutrients · doi:10.3390/nu16121938 · Cited by 46
Tsuda, T. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400871 · Cited by 44
Poša, M., & Sebenji, A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.11.008 · Cited by 41
Eelderink, C., Noort, M. W. J., Sözer, N., Koehorst, M., Holst, J. J., Deacon, C. F., Rehfeld, J. F., Poutanen, K. S., Vonk, R. J., Oudhuis, L. A. A. C. M., et al. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1156-6 · Cited by 42
Dietary Composition and Cardiovascular Risk: A Mediator or a Bystander?
Korakas, E., Dimitriadis, G., Raptis, A. E., & Lambadiari, V. (2018) · Nutrients · doi:10.3390/nu10121912 · Cited by 48
Relationship between intestinal microbiota, diet and biological systems: an integrated view
Ferreira, R. D. S., Mendonça, L. A. B. M., Ribeiro, C. F. A., Calças, N. C., Guimarães, R. D. C. A., do Nascimento, V. A., Freitas, K. D. C., Carvalho, C. M. E., de Castro, A. P., & Franco, O. L. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1836605 · Cited by 46
Krattinger, R., Boström, A. E. D., Lee, S. M. L., Thasler, W. E., Schiöth, H. B., Kullak-Ublick, G. A., & Mwinyi, J. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.04.037 · Cited by 41
Xie, Z., Jiang, H., Liu, W., Zhang, X., Chen, D., Sun, S.-M., Zhou, C., Liu, J., Bao, S., Wang, X., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02974-0 · Cited by 40
Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease
Shi, Q., Yuan, X., Zeng, Y., Wang, J., Zhang, Y., Chen, X., & Li, L. (2023) · Nutrients · doi:10.3390/nu15102411 · Cited by 41
Porcari, S., Fusco, W. G., Spivak, I., Fiorani, M., Gasbarrini, A., Elinav, E., Cammarota, G., & Ianiro, G. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00357-6 · Cited by 45
Tobón‐Cornejo, S., Sánchez‐Tapia, M., Guizar-Heredia, R., Villegas, L. V., Noriega, L. G., Furuzawa‐Carballeda, J., Hernández‐Pando, R., Vázquez-Manjarrez, N., Granados‐Portillo, O., López‐Barradas, A. M., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2465896 · Cited by 40
Self-citationAvicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators
Pellicciari, R., Gioiello, A., Sabbatini, P., Venturoni, F., Nuti, R., Colliva, C., Rizzo, G., Adorini, L., Pruzanski, M., Roda, A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200256d · Cited by 40
Self-citationHolst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 40
Obesity-Driven Gut Microbiota Inflammatory Pathways to Metabolic Syndrome
Silva, L. H. A. C., Galvão, J. G. F. M., da Silva, J. S. D. F., de Sales-Neto, J. M., & Rodrigues‐Mascarenhas, S. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00341 · Cited by 42
Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk
Koopen, A. M., Groen, A. K., & Nieuwdorp, M. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000357 · Cited by 41
Herbert, K. E., & Erridge, C. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx237 · Cited by 40
Al-Khaifi, A., Straniero, S., Voronova, V., Chernikova, D., Sokolov, V. V., Kumar, C., Angelin, B., & Rudling, M. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12811 · Cited by 42
Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?
Debédat, J., Amouyal, C., Aron‐Wisnewsky, J., & Clément, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00738-3 · Cited by 45
Zhang, F., Yuan, W., Wei, Y., Zhang, D., Duan, Y., Li, B., Wang, X., Xi, L., Zhou, Y., & Wu, X. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.031 · Cited by 40
Semisynthetic bile acids: a new therapeutic option for metabolic syndrome
Lazarević, S., Đanić, M., Goločorbin-Kon, S., Al‐Salami, H., & Mikov, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104333 · Cited by 40
Li, M., Zhou, W., Dang, Y., Li, C., Ji, G., & Zhang, L. R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110953 · Cited by 40
2‐Phenoxy‐nicotinamides are Potent Agonists at the Bile Acid Receptor GPBAR1 (TGR5)
Martin, R. E., Bissantz, C., Gavelle, O., Kuratli, C., Dehmlow, H., Richter, H. G., Obst-Sander, U., Erickson, S. D., Kim, K., Pietranico‐Cole, S. L., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200474 · Cited by 42
Zhangyin, S., Wang, X., Feng, S., Chaoju, X., Xing, Y., Guo, L., Zhao, J., & Ji, C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.934341 · Cited by 42
MetALD: Clinical aspects, pathophysiology and treatment
Gratacós‐Ginès, J., Ariño, S., Sancho‐Bru, P., Bataller, R. A., & Pose, E. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101250 · Cited by 45
Zhang, C., Zhang, Q., Zhang, X., Du, S., Zhang, Y. E., Wang, X., Liu, Y., Fang, B., Chen, J., Liu, R., et al. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.11.042 · Cited by 43
Peripheral targets in obesity treatment: a comprehensive update
Chatzigeorgiou, A., Kandaraki, E., Papavassiliou, A. G., & Koutsilieris, M. (2014) · Obesity Reviews · doi:10.1111/obr.12163 · Cited by 44
Mobraten, K., Haugbro, T., Karlstrom, E., Kleiveland, C. R., & Lea, T. (2014) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2014.986744 · Cited by 40
Phillips, D. P., Gao, W., Yang, Y., Zhang, G., Lerario, I. K., Lau, T. L. S., Jiang, J., Wang, X., Nguyen, D. G., Bhat, B. G., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401731q · Cited by 39
Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment
Zaborska, K. E., & Cummings, B. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1092-3 · Cited by 40
Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
Smeuninx, B., Boslem, E., & Febbraio, M. A. (2020) · Cancers · doi:10.3390/cancers12071714 · Cited by 39
Bile Formation and the Enterohepatic Circulation
Dawson, P. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00053-1 · Cited by 39
Rochoń, J., Kalinowski, P., Szymanek-Majchrzak, K., & Grąt, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i23.2964 · Cited by 41
Role of FXR in β-Cells of Lean and Obese Mice
Schittenhelm, B., Wagner, R., Kähny, V., Peter, A., Krippeit‐Drews, P., Düfer, M., & Drews, G. (2015) · Endocrinology · doi:10.1210/en.2014-1751 · Cited by 38
Elobixibat for the treatment of constipation
Wong, B., & Camilleri, M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.753056 · Cited by 47
The significance of the nuclear farnesoid X receptor (FXR) in β cell function
Düfer, M., Hörth, K., Krippeit‐Drews, P., & Drews, G. (2012) · Islets · doi:10.4161/isl.22383 · Cited by 41
Steroidal Scaffolds as FXR and GPBAR1 Ligands: From Chemistry to Therapeutical Application
Sepe, V., Distrutti, E., Limongelli, V., Fiorucci, S., & Zampella, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.54 · Cited by 37
Mazidi, M., Caravatto, P. P. D. P., Speakman, J. R., & COHEN, R. V. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2549-1 · Cited by 40
Bile acid changes after metabolic surgery are linked to improvement in insulin sensitivity
Ahlin, S., CEFALO, C. M. A., Bondia‐Pons, I., Capristo, E., Marini, L., Gastaldelli, A., Mingrone, G., & Nolan, J. J. (2019) · British journal of surgery · doi:10.1002/bjs.11208 · Cited by 39
Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes
Wu, Y., Zhou, A., Tang, L., Lei, Y., Tang, B., & Zhang, L. (2020) · Journal of Diabetes Research · doi:10.1155/2020/6138438 · Cited by 38
Gut microbiota and obesity: an overview of microbiota to microbial-based therapies
Sheykhsaran, E., Abbasi, A., Leylabadlo, H. E., Sadeghi, J., Mehri, S., Mazraeh, F. N., Feizi, H., & Baghi, H. B. (2022) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-141311 · Cited by 41
Ma, L., Yang, F., Wu, X. Y., Mao, C., Guo, L., Miao, T., Zang, S., Jiang, X., Shen, D., Wei, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117054119 · Cited by 36
Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets
Cheng, Z., Chen, Y., Schnabl, B., Chu, H., & Yang, L. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.06.009 · Cited by 41
Metadata
- Authors
- Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., Pellicciari, R., Auwerx, J., & Schoonjans, K.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Perugia (IT)
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Auwerx, Johan
- Schoonjans, Kristina
- ORCID
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 10
- Issue
- 3
- Pages
- 167-177
- ISSN
- 1550-4131 (ISSN-L)
- PMC
- PMC2739652
- OpenAlex
- W2081271380
- Cited by
- 1,885
- References
- 43
- Citations by year
- 2026: 143 · 2025: 100 · 2024: 153 · 2023: 112 · 2022: 135 · 2021: 141 · 2020: 148 · 2019: 113 · 2018: 124 · 2017: 126 · 2016: 106 · 2015: 108 · 2014: 87 · 2013: 91 · 2012: 69
- FWCI
- 47.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1415 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell Metabolism (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- European Commission
- Centre National de la Recherche Scientifique
- Australian Research Council
- National Institutes of Health
- Agence Nationale de la Recherche
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Nursing › Nutrition and Dietetics › Biochemical Analysis and Sensing Techniques
- Keywords
- TGR5, glucose homeostasis, glucagon-like peptide-1, enteroendocrine cells, energy expenditure, diet-induced obesity, diabesity, ATP/ADP ratio, calcium mobilization, brown adipose tissue, pancreatic function, liver function, TGR5 agonists, INT-777, incretin-based therapy
- MeSH terms
- Adenosine Triphosphate, Animals, Bile Acids and Salts, Calcium, Cell Line, Cholic Acids, Cricetulus, Glucose, Cricetinae, Homeostasis, Humans, Insulin, Male, Mice, Inbred C57BL, Mice, Obese, Oxidative Phosphorylation, Signal Transduction, CHO Cells, Mice, Knockout, Enteroendocrine Cells, Receptors, G-Protein-Coupled, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
